BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q2 EPS by 6c; Guides FY11
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $66.53 +0.15%
Revenue Growth %: +32.7%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Revenue Growth %: +32.7%
Financial Fact:
Selling, general and administrative: 118.76M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q2 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $110.63 million versus the consensus estimate of $105.9 million.
Sees FY2011 revenue of $436-$465 million, versus prior guidance of $422-$452 million and the consensus of $441.08 million.
Sees FY2011 revenue of $436-$465 million, versus prior guidance of $422-$452 million and the consensus of $441.08 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BioMarin Pharmaceutical Inc. (BMRN) PT Raised to $90; Piper Sandler: 'Remain Buyers'
- Oxford Industries (OXM) Tops Q2 EPS by 4c; offers guidance
- BRP Inc. (DOO) Reports Q2 Loss of Cd$0.18
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
